{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:59:47Z","timestamp":1778817587216,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF 2019R1C1C1010958"],"award-info":[{"award-number":["NRF 2019R1C1C1010958"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the diverse genetic mutations in head and neck cancer, the chemotherapy outcome for this cancer has not improved for decades. It is urgent to select prognostic factors and therapeutic targets for oropharyngeal cancer to establish precision medicine. Recent studies have identified PSMD1 as a potential prognostic marker in several cancers. We aimed to assess the prognostic significance of PSMD1 expression in oropharyngeal squamous cell carcinoma (OPSCC) patients using immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied 64 individuals with OPSCC tissue from surgery at Seoul National University Bundang Hospital between April 2008 and August 2017. Immunostaining analysis was conducted on the tissue microarray (TMA) sections (4\u00a0\u03bcm) for p16 and PSMD1. H-score, which scale from 0 to 300, was calculated from each nucleus, cytoplasm, and cellular expression. Clinicopathological data were compared with Chi-squared test, Fisher\u2019s exact test, t-test, and logistic regression. Survival data until 2021 were achieved from national statistical office\u00a0of Korea. Kaplan\u2013Meier method and cox-regression model were used for disease-specific survival (DSS) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      H-score of 90 in nucleus was appropriate cutoff value for \u2018High PSMD1 expression\u2019 in OPSCC. Tonsil was more frequent location in low PSMD1 group (42\/52, 80.8%) than in high PSMD1 group (4\/12, 33.3%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.002). Early-stage tumor was more frequent in in low PSMD1 group (45\/52, 86.5%) than in high PSMD1 group (6\/12, 50%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.005). HPV was more positive in low PSMD1 group (43\/52, 82.7%) than in high PSMD1 group (5\/12, 41.7%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.016). Patients with PSMD1 high expression showed poorer DSS than in patients with PSMD1 low expression (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.006 in log rank test). In multivariate analysis, PSMD1 expression, pathologic T staging, and specimen age were found to be associated with DSS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.011,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.025,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.029, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our study, we established PSMD1 as a negative prognostic factor in oropharyngeal squamous cell carcinoma, indicating its potential as a target for targeted therapy and paving the way for future in vitro studies on drug repositioning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-023-11689-2","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:01:38Z","timestamp":1702728098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["PSMD1 as a prognostic marker and potential target in oropharyngeal cancer"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-9368","authenticated-orcid":false,"given":"Hae Chan","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-8328","authenticated-orcid":false,"given":"Hyojin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7020-1320","authenticated-orcid":false,"given":"Ji-Yeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2643-3929","authenticated-orcid":false,"given":"Hye-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5421-5546","authenticated-orcid":false,"given":"Jinyi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-9474","authenticated-orcid":false,"given":"WonJae","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0759-6850","authenticated-orcid":false,"given":"Soon-Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8577-6964","authenticated-orcid":false,"given":"Woo-Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"issue":"3","key":"11689_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1743-7563.2011.01420.x","volume":"7","author":"DI Pryor","year":"2011","unstructured":"Pryor DI, Solomon B, Porceddu SV. The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. Asia Pac J Clin Oncol. 2011;7(3):236\u201351.","journal-title":"Asia Pac J Clin Oncol"},{"key":"11689_CR2","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3389\/fonc.2019.01522","volume":"9","author":"SV Porceddu","year":"2019","unstructured":"Porceddu SV, Scotte F, Aapro M, Salmio S, Castro A, Launay-Vacher V, Licitra L. Treating patients with locally advanced squamous cell carcinoma of the Head and Neck unsuitable to receive cisplatin-based therapy. Front Oncol. 2019;9:1522.","journal-title":"Front Oncol"},{"issue":"7","key":"11689_CR3","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1681\/ASN.2006010083","volume":"17","author":"SH Lecker","year":"2006","unstructured":"Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and Disease states. J Am Soc Nephrol. 2006;17(7):1807\u201319.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"11689_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI71602","volume":"124","author":"NM Weathington","year":"2014","unstructured":"Weathington NM, Mallampalli RK. Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014;124(1):6\u201312.","journal-title":"J Clin Invest"},{"issue":"6","key":"11689_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ejh.12749","volume":"96","author":"E Muchtar","year":"2016","unstructured":"Muchtar E, Gertz MA, Magen H. A practical review on carfilzomib in Multiple Myeloma. Eur J Haematol. 2016;96(6):564\u201377.","journal-title":"Eur J Haematol"},{"issue":"2","key":"11689_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","volume":"81","author":"MSF Roeten","year":"2018","unstructured":"Roeten MSF, Cloos J, Jansen G. Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother Pharmacol. 2018;81(2):227\u201343.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"11689_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.surg.2016.06.064","volume":"161","author":"PK Jonker","year":"2017","unstructured":"Jonker PK, van Dam GM, Oosting SF, Kruijff S, Fehrmann RS. Identification of novel therapeutic targets in anaplastic thyroid carcinoma using functional genomic mRNA-profiling: paving the way for new avenues? Surgery. 2017;161(1):202\u201311.","journal-title":"Surgery"},{"issue":"1","key":"11689_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/jb\/mvx053","volume":"163","author":"T Okumura","year":"2018","unstructured":"Okumura T, Ikeda K, Ujihira T, Okamoto K, Horie-Inoue K, Takeda S, Inoue S. Proteasome 26S subunit PSMD1 regulates Breast cancer cell growth through p53 protein degradation. J Biochem. 2018;163(1):19\u201329.","journal-title":"J Biochem"},{"issue":"18","key":"11689_CR9","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.7150\/jca.31543","volume":"10","author":"W Xiong","year":"2019","unstructured":"Xiong W, Wang W, Huang H, Jiang Y, Guo W, Liu H, Yu J, Hu Y, Wan J, Li G. Prognostic significance of PSMD1 expression in patients with gastric Cancer. J Cancer. 2019;10(18):4357\u201367.","journal-title":"J Cancer"},{"key":"11689_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejphar.2016.03.031","volume":"780","author":"K Boland","year":"2016","unstructured":"Boland K, Flanagan L, McCawley N, Pabari R, Kay EW, McNamara DA, Murray F, Byrne AT, Ramtoola Z, Concannon CG, et al. Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon Cancer. Eur J Pharmacol. 2016;780:53\u201364.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"11689_CR11","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","volume":"66","author":"M Bazzaro","year":"2006","unstructured":"Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB. Ubiquitin-proteasome system stress sensitizes Ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 2006;66(7):3754\u201363.","journal-title":"Cancer Res"},{"issue":"9","key":"11689_CR12","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.3390\/cells10092390","volume":"10","author":"AJ Rubio","year":"2021","unstructured":"Rubio AJ, Bencomo-Alvarez AE, Young JE, Velazquez VV, Lara JJ, Gonzalez MA, Eiring AM: 26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy. Cells 2021, 10(9):2390.","journal-title":"Cells"},{"issue":"12","key":"11689_CR13","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s00106-017-0391-3","volume":"65","author":"J Doescher","year":"2017","unstructured":"Doescher J, Veit JA, Hoffmann TK. [The 8th edition of the AJCC Cancer staging Manual: updates in otorhinolaryngology, head and neck Surgery]. HNO. 2017;65(12):956\u201361.","journal-title":"HNO"},{"issue":"1","key":"11689_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12967-020-02396-8","volume":"18","author":"S Kwon","year":"2020","unstructured":"Kwon S, Ahn SH, Jeong WJ, Jung YH, Bae YJ, Paik JH, Chung JH, Kim H. Estrogen receptor \u03b1 as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma. J Transl Med. 2020;18(1):240.","journal-title":"J Transl Med"},{"key":"11689_CR15","unstructured":"The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000173692-PSMD1\/pathology\/head+and+neck+cancer. Accessed 18 Dec 2022."},{"key":"11689_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2407-14-152","volume":"14","author":"C Lagadec","year":"2014","unstructured":"Lagadec C, Vlashi E, Bhuta S, Lai C, Mischel P, Werner M, Henke M, Pajonk F. Tumor cells with low proteasome subunit expression predict overall survival in Head and Neck cancer patients. BMC Cancer. 2014;14:152.","journal-title":"BMC Cancer"},{"issue":"9","key":"11689_CR17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00405-020-05979-9","volume":"277","author":"P Machczynski","year":"2020","unstructured":"Machczynski P, Majchrzak E, Niewinski P, Marchlewska J, Golusinski W. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Otorhinolaryngol. 2020;277(9):2407\u201312.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"11689_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41419-018-0806-4","volume":"9","author":"P Tsvetkov","year":"2018","unstructured":"Tsvetkov P, Adler J, Myers N, Biran A, Reuven N, Shaul Y. Oncogenic addiction to high 26S proteasome level. Cell Death Dis. 2018;9(7):773.","journal-title":"Cell Death Dis"},{"issue":"4","key":"11689_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/cas.12369","volume":"105","author":"H Maruyama","year":"2014","unstructured":"Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T, Takenaka Y, Nakahara S, Todo T, Hongyo T, et al. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci. 2014;105(4):409\u201317.","journal-title":"Cancer Sci"},{"issue":"4","key":"11689_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3342\/ceo.2012.5.4.207","volume":"5","author":"TW Kim","year":"2012","unstructured":"Kim TW, Choi SY, Ko YH, Baek CH, Son YI. The prognostic role of p16 expression in Tonsil Cancer treated by either Surgery or Radiation. Clin Exp Otorhinolaryngol. 2012;5(4):207\u201312.","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"6","key":"11689_CR21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4161\/cc.23882","volume":"12","author":"C Li","year":"2013","unstructured":"Li C, Johnson DE. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle. 2013;12(6):923\u201334.","journal-title":"Cell Cycle"},{"issue":"4","key":"11689_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.15430\/JCP.2018.23.4.153","volume":"23","author":"HH Jang","year":"2018","unstructured":"Jang HH. Regulation of protein degradation by Proteasomes in Cancer. J Cancer Prev. 2018;23(4):153\u201361.","journal-title":"J Cancer Prev"},{"issue":"2","key":"11689_CR23","doi-asserted-by":"publisher","first-page":"113075","DOI":"10.1016\/j.yexcr.2022.113075","volume":"413","author":"L Liu","year":"2022","unstructured":"Liu L, Liu A, Dong J, Zuo Z, Liu X. Proteasome 26S subunit, non-ATPase 1 (PSMD1) facilitated the progression of lung adenocarcinoma by the de-ubiquitination and stability of PTEN-induced kinase 1 (PINK1). Exp Cell Res. 2022;413(2):113075.","journal-title":"Exp Cell Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11689-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:02:43Z","timestamp":1702728163000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11689-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11689"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11689-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3218107\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,16]]},"assertion":[{"value":"30 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval from the Institutional Review Board of Seoul National University Bundang Hospital, and informed consent was waived (IRB No. B-2211\u2013790-305).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1242"}}